Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||ATX101 + Carboplatin + Pegylated liposomal doxorubicin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ATX101||ATX-101|ATX 101||ATX101 is a peptide that targets PCNA, leading to decreased PCNA expression and inhibition of Akt and mTORC signaling, and potentially resulting in reduced tumor cell proliferation and inhibition of tumor growth (PMID: 35053455).|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 7||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Pegylated liposomal doxorubicin||Doxil||ATI-0918|CAELYX|liposomal doxorubicin||Chemotherapy - Anthracycline 13||Doxil (pegylated liposomal doxorubicin) comprises the anthracyline doxorubicin, which intercalates into DNA and disrupts DNA replication, encapsulated in a liposome, which improves tumor penetration and decreases toxicity (NCI Drug Dictionary), and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04814875||Phase Ib/II||ATX101 + Carboplatin + Pegylated liposomal doxorubicin||A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy||Recruiting||AUS||0|